PBLS Stock — Parabilis Medicines, Inc. Common Stock

Parabilis Medicines, Inc. Common Stock (PBLS)

Updated October 16, 2026.

PBLS is a Stock. Total return is -28.0% over the past 0.4 years, 33.7 points behind SPY at 5.7%.

Parabilis Medicines is a clinical-stage biopharmaceutical company developing helical peptide therapeutics designed to target proteins traditionally considered undruggable, including functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead program called FOG-001 for cancer treatment. The company does not currently distribute dividends. As an early-stage biotech company with no approved products, it may appeal to investors seeking exposure to innovative drug development and the potential for significant long-term capital appreciation, though it carries substantial clinical and commercial risk.

PBLS performance versus SPY

Price and return data through 2026-10-16.

Total return is -28.0% over the past 0.4 years, 33.7 points behind SPY at 5.7%.

PBLS key facts

Asset type

Stock

Asset class

Equity

Inception date

06/10/2026

Distribution frequency

None

Last close

$22.75 (as of 2026-10-16)

Market cap

$2,774,408,682

Average volume

1115052.0

Payout ratio

0.0%

EPS

$-9.18

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PBLS risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider PBLS — and who may not

It is a weaker fit for investors who need monthly cash flow (PBLS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PBLS

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions